- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: Electronic cigarettes.
Displaying page 1 of 2.
EudraCT Number: 2017-003588-37 | Sponsor Protocol Number: P150952J | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A randomized, placebo controlled, double blind, double dummy, multicenter trial comparing electronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine | |||||||||||||
Medical condition: Smokers smoking at least 10 cigarettes/day in the past year | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000339-42 | Sponsor Protocol Number: W1206810 | Start Date*: 2016-08-29 | |||||||||||
Sponsor Name:CENTRO PER LA PREVENZIONE E CURA DEL TABAGISMO | |||||||||||||
Full Title: Efficacy of smoking cessation with varenicline for e-cigarettes users: a randomized controlled trial (VAREVAPE) | |||||||||||||
Medical condition: problems related to the use of nicotine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005565-20 | Sponsor Protocol Number: QMUL111111 | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:QUEEN MARY, UNIVERSITY OF LONDON | |||||||||||||
Full Title: Comparison of the effects of the electronic cigarette and nicotine inhalator on tobacco withdrawal symptoms over 24 hours of abstinence | |||||||||||||
Medical condition: Nicotine withdrawal state | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000038-11 | Sponsor Protocol Number: RA/PR/033012/002/05 | Start Date*: 2006-07-10 | |||||||||||
Sponsor Name:CHIESI Farmaceutici S.p.A | |||||||||||||
Full Title: EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2μg + 200μg qd or 1μg + ... | |||||||||||||
Medical condition: Moderate persistent asthma sub optimally controlled on existing therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001237-65 | Sponsor Protocol Number: | Start Date*: 2017-06-29 | ||||||||||||||||
Sponsor Name:Queen Mary University of London, Joint Research Management Office | ||||||||||||||||||
Full Title: Helping Pregnant smokers quit: A multi-centre RCT of electronic cigarettes and nicotine patches | ||||||||||||||||||
Medical condition: Tobacco dependence/smoking cessation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023326-20 | Sponsor Protocol Number: 1268.17 | Start Date*: 2010-12-29 |
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | ||
Full Title: A randomized, double blind, placebo and active controlled, parallel group study to evaluate the safety and efficacy of 6-week treatment with oral doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.... | ||
Medical condition: Mild asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-005107-17 | Sponsor Protocol Number: 1184.15 | Start Date*: 2008-01-28 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim bv | ||||||||||||||||||
Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal... | ||||||||||||||||||
Medical condition: Moderate to severe COPD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) FR (Completed) SE (Prematurely Ended) DK (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) SK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005134-36 | Sponsor Protocol Number: 1184.14 | Start Date*: 2008-01-28 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim bv | ||||||||||||||||||
Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal... | ||||||||||||||||||
Medical condition: Moderate to severe COPD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) PT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) DK (Completed) FR (Completed) SE (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) GR (Completed) LT (Prematurely Ended) EE (Prematurely Ended) SK (Completed) AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004564-35 | Sponsor Protocol Number: 205739 | Start Date*: 2018-08-14 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd. | |||||||||||||
Full Title: A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Particip... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD)/chronic bronchitis and emphysema | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013235-38 | Sponsor Protocol Number: CQVA149A2307 | Start Date*: 2010-03-25 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderat... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) GB (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002046-31 | Sponsor Protocol Number: KFL3503 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Mundipharma Research Limited | |||||||||||||
Full Title: A randomised, single blind, cross-over study to compare a fixed dose combination of fluticasone propionate / formoterol fumarate (fluticasone /formoterol breath actuated inhaler (BAI)) with a fixe... | |||||||||||||
Medical condition: Fixed airflow obstruction with elevated eosinophils | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Prematurely Ended) ES (Completed) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008394-63 | Sponsor Protocol Number: CNVA237A2303 | Start Date*: 2009-10-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 52-week treatment, randomized, double-blind, placebo-controlled, with open label tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chroni... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) HU (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023621-37 | Sponsor Protocol Number: CQVA149A2313 | Start Date*: 2011-02-23 | |||||||||||
Sponsor Name:Novartis Farmacéutica S. A | |||||||||||||
Full Title: Estudio multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento, de grupos paralelos, de 26 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de QVA149 en compa... | |||||||||||||
Medical condition: EPOC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) HU (Completed) BE (Completed) LT (Completed) EE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017772-25 | Sponsor Protocol Number: CQVA149A2303 | Start Date*: 2010-10-11 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) ES (Completed) FR (Completed) DE (Completed) GB (Completed) BG (Completed) NL (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000822-30 | Sponsor Protocol Number: 205.346 | Start Date*: 2006-10-25 |
Sponsor Name:Boehringer Ingelheim Pharma GmbH | ||
Full Title: A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aeroso... | ||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) including chronic bronchitis and emphysema | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) LT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003675-21 | Sponsor Protocol Number: 205724 | Start Date*: 2017-06-01 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo ... | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) NL (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000046-21 | Sponsor Protocol Number: C0524T03 | Start Date*: 2004-11-22 |
Sponsor Name:Centocor BV | ||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Su... | ||
Medical condition: Severe persistent asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Prematurely Ended) SE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006519-60 | Sponsor Protocol Number: D5892C00014 | Start Date*: 2007-05-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A multi-centre, randomised, double-blind, cross-over design study to evaluate efficacy on exercise tolerance of budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 μg one inhalation twice daily com... | |||||||||||||
Medical condition: Severe Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001337-34 | Sponsor Protocol Number: D5892C00016 | Start Date*: 2007-08-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/f... | |||||||||||||
Medical condition: Severe Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001148-37 | Sponsor Protocol Number: 200182 | Start Date*: 2018-05-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A randomized, double-blind (sponsor unblind), placebo-controlled, multi-centered phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen ... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
